Andrew John Partridge Turning Point Therapeutics, Inc. (TPTX) insider trading activity

TPTX Quotes by TradingView

Andrew John Partridge is EVP & Chief Commercial Officer of Turning Point Therapeutics, Inc.. Currently has a direct ownership of 22,078 shares of TPTX, which is worth approximately $0. The most recent transaction as insider was on Feb 09, 2022, when has been sold 221 shares (Common Stock) at a price of $36.3 per share, resulting in proceeds of $8,022. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 22.1K
0% 3M change
0% 12M change
Total Value Held $0

Andrew John Partridge Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 09 2022
SELL
Open market or private sale
$8,022 $36.3 p/Share
221 Reduced 0.99%
22,078 Common Stock
Feb 09 2022
BUY
Grant, award, or other acquisition
-
16,283 Added 29.8%
38,361 Common Stock
Jul 14 2021
SELL
Open market or private sale
$139,988 $74.9 p/Share
1,869 Reduced 7.91%
21,767 Common Stock
Feb 08 2021
BUY
Grant, award, or other acquisition
-
2,136 Added 8.29%
23,636 Common Stock
Jul 13 2020
BUY
Grant, award, or other acquisition
-
21,500 Added 50.0%
21,500 Common Stock
AJP

Andrew John Partridge

EVP & Chief Commercial Officer
San Diego, CA

Track Institutional and Insider Activities on TPTX

Follow Turning Point Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TPTX shares.

Notify only if

Insider Trading

Get notified when an Turning Point Therapeutics, Inc. insider buys or sells TPTX shares.

Notify only if

News

Receive news related to Turning Point Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on TPTX